PCSK9 and familial hyperaldosteronism: Since the use of PCSK9 inhibitors has emerged outside conventional FH treatment strategies, their gradually increasing applications in clinical practice have not only brought good news to FH patients but also new hope for patients with hyperlipidemia that are at high risk of CAD.